The 441 Morgan Avenue development in Cambridge Crossing (Astellas)
August 9, 2023 07:30 PM EDT
Bioregnum

Astel­las builds its R&D foot­print in Cam­bridge/Boston with an add-on for labs, of­fices

Astel­las is snap­ping in an­oth­er piece of the re­al es­tate puz­zle for its glob­al R&D re­or­ga­ni­za­tion.

Just as it wraps one project to piece …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Judge halts some NIH cuts af­ter 22 states sue

States sue Trump ad­min­is­tra­tion over bil­lions in NIH in­di­rect cost cuts

Hims’ Su­per Bowl ad has drawn crit­i­cism from law­mak­ers — and now No­vo Nordisk

Eli Lil­ly inks $630M deal for Phase 1 MASH can­di­date

Mer­ck KGaA con­firms in­ter­est in ac­quir­ing can­cer biotech Spring­Works

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times